A J Zurita1, L L Pisters2, X Wang3, P Troncoso4, P Dieringer1, J F Ward2, J W Davis2, C A Pettaway2, C J Logothetis1, L C Pagliaro1. 1. Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA. 2. Department of Urology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA. 3. Department of Biostatistics, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA. 4. Department of Pathology, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.
Abstract
BACKGROUND: Prostate cancer persisting in the primary site after systemic therapy may contribute to emergence of resistance and progression. We previously demonstrated molecular characteristics of lethal cancer in the prostatectomy specimens of patients presenting with lymph node metastasis after chemohormonal treatment. Here we report the post-treatment outcomes of these patients and assess whether a link exists between surgery and treatment-free/cancer-free survival. METHODS: Patients with either clinically detected lymph node metastasis or primaries at high risk for nodal dissemination were treated with androgen ablation and docetaxel. Those responding with PSA concentration <1 ng ml(-1) were recommended surgery 1 year from enrollment. ADT was withheld postoperatively. The rate of survival without biochemical progression 1 year after surgery was measured to screen for efficacy. RESULTS: Forty patients were enrolled and 39 were evaluable. Three patients (7.7%) declined surgery. Of the remaining 36, 4 patients experienced disease progression during treatment and 4 more did not reach PSA <1. Twenty-six patients (67%) completed surgery, and 13 (33%) were also progression-free 1 year postoperatively (8 with undetectable PSA). With a median follow-up of 61 months, time to treatment failure was 27 months in the patients undergoing surgery. The most frequent patterns of first disease recurrence were biochemical (10 patients) and systemic (5). CONCLUSIONS: Half of the patients undergoing surgery were off treatment and progression-free 1 year following completion of all therapy. These results suggest that integration of surgery is feasible and may be superior to systemic therapy alone for selected prostate cancer patients presenting with nodal metastasis.
BACKGROUND:Prostate cancer persisting in the primary site after systemic therapy may contribute to emergence of resistance and progression. We previously demonstrated molecular characteristics of lethal cancer in the prostatectomy specimens of patients presenting with lymph node metastasis after chemohormonal treatment. Here we report the post-treatment outcomes of these patients and assess whether a link exists between surgery and treatment-free/cancer-free survival. METHODS:Patients with either clinically detected lymph node metastasis or primaries at high risk for nodal dissemination were treated with androgen ablation and docetaxel. Those responding with PSA concentration <1 ng ml(-1) were recommended surgery 1 year from enrollment. ADT was withheld postoperatively. The rate of survival without biochemical progression 1 year after surgery was measured to screen for efficacy. RESULTS: Forty patients were enrolled and 39 were evaluable. Three patients (7.7%) declined surgery. Of the remaining 36, 4 patients experienced disease progression during treatment and 4 more did not reach PSA <1. Twenty-six patients (67%) completed surgery, and 13 (33%) were also progression-free 1 year postoperatively (8 with undetectable PSA). With a median follow-up of 61 months, time to treatment failure was 27 months in the patients undergoing surgery. The most frequent patterns of first disease recurrence were biochemical (10 patients) and systemic (5). CONCLUSIONS: Half of the patients undergoing surgery were off treatment and progression-free 1 year following completion of all therapy. These results suggest that integration of surgery is feasible and may be superior to systemic therapy alone for selected prostate cancerpatients presenting with nodal metastasis.
Authors: Robert Dreicer; Cristina Magi-Galluzzi; Ming Zhou; Jason Rothaermel; Alwyn Reuther; James Ulchaker; Craig Zippe; Amr Fergany; Eric A Klein Journal: Urology Date: 2004-06 Impact factor: 2.649
Authors: Edward M Messing; Judith Manola; Jorge Yao; Maureen Kiernan; David Crawford; George Wilding; P Anthony di'SantAgnese; Donald Trump Journal: Lancet Oncol Date: 2006-06 Impact factor: 41.316
Authors: Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart Journal: Lancet Date: 2005 Aug 13-19 Impact factor: 79.321
Authors: Matthias D Hofer; Rainer Kuefer; Wei Huang; Haojie Li; Tarek A Bismar; Sven Perner; Richard E Hautmann; Martin G Sanda; Juergen E Gschwend; Mark A Rubin Journal: Urology Date: 2006-05 Impact factor: 2.649
Authors: Phillip G Febbo; Jerome P Richie; Daniel J George; Massimo Loda; Judith Manola; Sridhar Shankar; Agnieska Szot Barnes; Clare Tempany; William Catalona; Philip W Kantoff; William K Oh Journal: Clin Cancer Res Date: 2005-07-15 Impact factor: 12.531
Authors: L Cheng; E J Bergstralh; J C Cheville; J Slezak; F A Corica; H Zincke; M L Blute; D G Bostwick Journal: Am J Surg Pathol Date: 1998-12 Impact factor: 6.394
Authors: Badrinath R Konety; James A Eastham; Vicor E Reuter; Peter T Scardino; S Machele Donat; Guido Dalbagni; Paul Russo; Harry W Herr; Larry Schwartz; Philip W Kantoff; Howard Scher; W Kevin Kelly Journal: J Urol Date: 2004-02 Impact factor: 7.450
Authors: Gaëtan Devos; Wout Devlies; Gert De Meerleer; Marcella Baldewijns; Thomas Gevaert; Lisa Moris; Daimantas Milonas; Hendrik Van Poppel; Charlien Berghen; Wouter Everaerts; Frank Claessens; Steven Joniau Journal: Nat Rev Urol Date: 2021-09-15 Impact factor: 14.432